Brief: Quest Diagnostics Long-Term Outlook Beyond 2025 4%-5% Revenue Cagr, 7%-9% Adjusted EPS Cagr
12/01/2026 23:12
Jan 12 (Reuters) - SEC Filing: QUEST DIAGNOSTICS: LONG-TERM OUTLOOK BEYOND 2025: 4%-5% REVENUE CAGR, 7%-9% ADJUSTED EPS CAGR Source text: [ID:n0000947871-26-000025] Further company coverage: DGX.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quest Diagnostics
See all newsUS RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
U.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Quest Diagnostics - Reports Unauthorized Access To Quanum Lsm System On Oct 21, 2026
Laboratory operator Quest reports cyber breach affecting patient records
Quest Diagnostics down after cyber incident disclosure